Search results for "Blood glucose"

showing 10 items of 437 documents

Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour.

1994

Experiments on s.c. rat tumours (DS sarcoma) were performed to determine whether chronic or acute changes in tumour perfusion necessarily lead to changes in tissue oxygenation and bioenergetic status since, as a rule, blood flow is thought to be the ultimate determinant of the tumour bioenergetic status. Based on this study, there is clear experimental evidence that growth-related or acute (following i.v. administration of tumour necrosis factor alpha) decreases in tumour blood flow are accompanied by parallel alterations in tissue oxygenation. In contrast, tumour energy status remains stable as long as flow values do not fall below 0.4-0.5 ml g-1 min-1, and provided that glucose as the mai…

Blood GlucoseCancer ResearchPathologymedicine.medical_specialtyBioenergeticsPartial PressureHemodynamicsBiologyRats Sprague-DawleyAdenosine TriphosphateOxygen ConsumptionTumour perfusionmedicineAnimalsCompartment (ship)Body WeightOxygenationBlood flowNeoplasms Experimentalmedicine.diseaseRatsOxygenTissue oxygenationOncologyRegional Blood FlowSarcomaSarcoma ExperimentalEnergy MetabolismNeoplasm TransplantationResearch ArticleBritish Journal of Cancer
researchProduct

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

2018

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially pr…

Blood GlucoseCardiometabolic parameterGlucagon-Like PeptidesIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologyBioinformaticsIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEndothelial dysfunctionMolecular BiologyGlucagon-like peptide 1 receptorLiraglutidebusiness.industryType 2 Diabetes MellitusLiraglutideCardiovascular riskmedicine.diseasePlaque AtheroscleroticType 2 diabetes mellituBlood pressureDiabetes Mellitus Type 2Cardiovascular DiseasesMetabolic control analysisGlucagon-like peptide 1 receptor agonistMolecular Medicinebusinessmedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Role of NO-synthases and cyclooxygenases in the hyperreactivity of male rabbit carotid artery to testosterone under experimental diabetes.

2009

Abstract Cardiovascular disease is the major cause of morbidity and mortality in diabetic patients, which in turn is also associated with low levels of serum testosterone. The working hypothesis was that diabetes might modify the mechanisms involved in the vascular actions of testosterone in isolated rabbit carotid arteries. Testosterone (10 −8 –3 × 10 −4  M) induced a concentration-dependent relaxation of precontracted carotid arteries, which was higher in diabetic than in control rabbits. In control rabbits neither endothelium removal nor the nitric oxide synthase (NOS) inhibitor N G -nitro- l -arginine ( l -NOArg, 10 −5  M) modified the relaxant action of testosterone, and the cyclooxyge…

Blood GlucoseCarotid Artery DiseasesMalemedicine.medical_specialtyArginineEndotheliumCharybdotoxinNitric Oxide Synthase Type IIIThromboxaneBlotting WesternIndomethacinNitric Oxide Synthase Type IIVasodilationProstacyclinNitric OxideNitroarginineDiabetes Mellitus ExperimentalImmunoenzyme TechniquesThromboxane A2Internal medicinemedicinePotassium Channel BlockersAnimalsCyclooxygenase InhibitorsTestosteronePharmacologybiologyDose-Response Relationship Drugbusiness.industryTestosterone (patch)EpoprostenolNitric oxide synthaseVasodilationEndocrinologymedicine.anatomical_structureCarotid ArteriesApaminCyclooxygenase 2cardiovascular systembiology.proteinPotassiumCalciumCyclooxygenaseEndothelium VascularRabbitsbusinessDiabetic Angiopathiesmedicine.drugPharmacological research
researchProduct

Association Between Carotid Atherosclerosis and Metabolic Syndrome: Results From the ISMIR Study

2010

The metabolic syndrome (MetS) has previously been associated with an early marker of atherosclerosis, the carotid intima-media thickness (IMT). From the ISMIR (Ispessimento Medio Intimale e Rischio cardiovascolare [media-intima thickness and cardiovascular risk]) study population of 479 asymptomatic participants, we identified 80 participants with MetS. Carotid IMT and plaques were evaluated by ultrasonography. Blood samples were obtained from all participants. Participants with MetS had a significantly higher prevalence of a carotid IMT > 0.80 mm (P = .004) and of carotid plaques (P < .001) as compared with participants without MetS. Carotid IMT was significantly correlated with fas…

Blood GlucoseCarotid Artery DiseasesMalemedicine.medical_specialtycarotid intima-media thickness; carotid plaques; fibrinogen; metabolic syndrome; triglyceridescarotid intima-media thicknessFibrinogenAsymptomaticchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesTriglyceridesAgedMetabolic SyndromeCreatinineVascular diseasebusiness.industrycarotid plaquesFibrinogenMiddle Agedmedicine.diseaseUric AcidCross-Sectional Studiesmedicine.anatomical_structureEndocrinologyItalychemistryCreatininecardiovascular systemCardiologyUric acidPopulation studyFemalemedicine.symptomMetabolic syndromeTunica IntimaTunica MediaCardiology and Cardiovascular Medicinebusinessmedicine.drugArteryAngiology
researchProduct

The influence of different generations of computer algorithms on diabetes control

1990

With all control schedules, the management of diabetes is possible using Skyler's algorithm. In general, those control algorithms which do not allow the individual adaptation to changing conditions lead to overinsulinisation. So-called meal-related algorithms do usually minimise the fluctuations in blood sugar. The introduction of self-adapting algorithms, detecting peripheral insulin resistance, may further improve metabolic diabetes control.

Blood GlucoseControl algorithmbusiness.industryControl (management)Blood sugarHealth InformaticsPeripheral insulin resistancemedicine.diseaseDrug Administration ScheduleComputer Science ApplicationsEatingDiabetes controlTherapy Computer-AssistedDiabetes mellitusDiabetes MellitusmedicineHumansInsulinProspective StudiesAdaptation (computer science)businessAlgorithmAlgorithmsSoftwareRetrospective StudiesComputer Methods and Programs in Biomedicine
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy

2022

Cushing’s disease (CD) causes diabetes mellitus (DM) through different mechanisms in a significant proportion of patients. Glucose metabolism has rarely been assessed with appropriate testing in CD; we aimed to evaluate hormonal response to a mixed meal tolerance test (MMTT) in CD patients and analyzed the effect of pasireotide (PAS) on glucose homeostasis. To assess gastro-entero-pancreatic hormones response in diabetic (DM+) and non-diabetic (DM–) patients, 26 patients with CD underwent an MMTT. Ten patients were submitted to a second MMTT after two months of PAS 600 µg twice daily. The DM+ group had significantly higher BMI, waist circumference, glycemia, HbA1c, ACTH le…

Blood GlucoseCushing’s disease; diabetes mellitus; incretin; mixed meal test tolerance test; pasireotidemixed meal test tolerance testGastric Inhibitory PolypeptideIncretinsCatalysisInorganic ChemistryGlucagon-Like Peptide 1HumansInsulinPhysical and Theoretical ChemistryPituitary ACTH HypersecretionMolecular BiologyMealsSpectroscopyGlycated HemoglobinpasireotideC-Peptidediabetes mellituOrganic Chemistrydigestive oral and skin physiologyGeneral MedicineCushing’s diseaseGlucagonincretinComputer Science ApplicationsDiabetes Mellitus Type 2Cushing’s disease; mixed meal test tolerance test; diabetes mellitus; incretin; pasireotidediabetes mellituspasireotide.Insulin ResistanceSomatostatinhormones hormone substitutes and hormone antagonists
researchProduct

Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes—…

2015

Purpose: The optimal macronutrient composition of the diet for the management of type 2 diabetes is debated, particularly with regard to the ideal proportion of fat and carbohydrates. The aim of the study was to explore the association of different proportions of fat and carbohydrates of the diet—within the ranges recommended by different guidelines—with metabolic risk factors. Methods: We studied 1785 people with type 2 diabetes, aged 50–75, enrolled in the TOSCA.IT Study. Dietary habits were assessed using a validated food-frequency questionnaire (EPIC). Anthropometry, fasting lipids, HbA1c and C-reactive protein (CRP) were measured. Results: Increasing fat intake from <25 to ≥35 % is …

Blood GlucoseDietary FiberMale0301 basic medicineGlycated Hemoglobin AGlucose controlMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - Endocrinologia0302 clinical medicineRisk FactorsSurveys and QuestionnairesDietary fatfat plsam lipids low-grade inflammationNutritional guidelinesNutrition and DieteticsbiologyType 2 diabetesMiddle AgedHDL-cholesterolCholesterolC-Reactive ProteinCarbohydrates diet fat Glucose control HDL-cholesterol Nutritional guidelines Triglycerides Type 2 diabetesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetesFemaleDietary ProteinsType 2Dietary Carbohydratesmedicine.medical_specialtyHDLCarbohydrates030209 endocrinology & metabolismLDL03 medical and health sciencesInternal medicineGlucose controlPlasma lipidsDiabetes MellitusDietary CarbohydratesmedicineHumansIn patientCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Medicine (miscellaneous); Nutrition and DieteticsTriglyceridesAgedGlycated HemoglobinInflammation030109 nutrition & dieteticsbusiness.industryCholesterol HDLC-reactive proteinCholesterol LDLAnthropometrymedicine.diseaseDietary FatsDietEndocrinologyDiabetes Mellitus Type 2Fatbiology.proteinDiet · Carbohydrates · Fat · Glucose control · HDL-cholesterol · Triglycerides · Type 2 diabetes · Nutritional guidelinesCarbohydrates; Diet; Fat; Glucose control; HDL-cholesterol; Nutritional guidelines; Triglycerides; Type 2 diabetes; Aged; Blood Glucose; C-Reactive Protein; Cholesterol HDL; Cholesterol LDL; Diabetes Mellitus Type 2; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Energy Intake; Female; Glycated Hemoglobin A; Humans; Inflammation; Male; Middle Aged; Risk Factors; Surveys and Questionnaires; TriglyceridesEnergy IntakebusinessEuropean Journal of Nutrition
researchProduct

Effect of Fibre-Enriched Orange Juice on Postprandial Glycaemic Response and Satiety in Healthy Individuals: An Acute, Randomised, Placebo-Controlled…

2019

Background: Consumption of fibre-enriched orange juice may be an appropriate way to supplement daily fibre intake and achieve beneficial effects on metabolic health. The present study aimed to assess the short-term effects of fibre-enriched orange juice on postprandial metabolism and satiety in a healthy adult population. Methods: In this double-blind, randomised, placebo-controlled, crossover study 10 healthy subjects underwent two one-day trials in which they consumed an orange juice beverage containing 1.4 g/100 mL of citrus fibre (29.3% soluble and 41.9% insoluble) or a placebo (regular orange juice without added fibre). Postprandial glucose, insulin, gut hormones (GLP1, GIP and ghrelin…

Blood GlucoseDietary FiberMale0301 basic medicineTime Factorsgut hormonesmedicine.medical_treatmentsatietyAppetite0302 clinical medicineBlood serumGlucagon-Like Peptide 1media_commonCross-Over StudiesNutrition and DieteticsLeptinglycaemiaPostprandial PeriodGhrelinHealthy VolunteersFruit and Vegetable JuicesPostprandialFemaleCitrus sinensisAdultmedicine.medical_specialtyinsulinmedia_common.quotation_subjectBlood sugar030209 endocrinology & metabolismSatiationArticlecitrus fibreYoung Adult03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansOrange juice030109 nutrition & dieteticsbusiness.industryInsulinAppetiteCrossover studyEndocrinologyGlycemic Indexorange juicehealthy subjectsbusinessFood ScienceNutrients
researchProduct

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

2022

Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most common chronic diseases worldwide due to social and economic developments that have led to unhealthy lifestyles, with a considerable impact both in terms of morbidity and mortality. The management of T2DM, before starting specific therapies, includes cornerstones such as healthy eating, regular exercise and weight loss. Strict adherence to the Mediterranean diet (MedDiet) has been related to an inverse association with the risk of T2DM onset, as well as an improvement in glycaemic control; in particular, thanks to the consumption of extra virgin olive oil (EVOO). Agonists of gut-derived glucagon-like…

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agent[SDV]Life Sciences [q-bio]Organic ChemistryEVOOT2DMGeneral MedicineIncretinIncretinsCatalysisComputer Science ApplicationsInorganic ChemistryDiabetes Mellitus Type 2Glucagon-Like Peptide 1Insulin SecretionHumansHypoglycemic AgentsMedDietPhysical and Theoretical ChemistryGLP-1Molecular BiologySpectroscopyHuman
researchProduct